- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03815890
Novel IO와 Nivolumab을 병용한 유방암에 대한 수술 전 시험 (BELLINI)
Novel IO와 Nivolumab을 병용한 유방암에 대한 수술 전 2상 시험(BELLINI 시험)
To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.
연구 개요
상세 설명
The investigators aim to test the activity of nivolumab monotherapy in primary breast tumors in a pre-operative window of opportunity trial. As the data of the investigators generated in the TONIC trial (metastatic TNBC) indicate that low dose doxorubicin may 'prime' the tumor microenvironment (TME) resulting in higher response rates on nivolumab, in addition, cohorts for treatment with nivolumab plus low dose doxorubicin will be opened. Given the emerging data on other immunomodulatory strategies, this platform study allows opening additional cohorts for promising novel immune-oncology (IO) drugs for which a strong efficacy signal has been seen without drug safety issues. The investigators will study the TME and systemic host factors with specific emphasis on immunosuppressive processes that can potentially be targeted by novel IO agents to further optimize BC immunotherapy.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: M Kok, MD
- 전화번호: 9111 3120512
- 이메일: m.kok@nki.nl
연구 연락처 백업
- 이름: I Nederlof
- 전화번호: 9111 3120512
- 이메일: i.nederlof@nki.nl
연구 장소
-
-
-
Amsterdam, 네덜란드, 1066CX
- 모병
- NKI-AVL
-
연락하다:
- M Kok, MD
- 이메일: m.kok@nki.nl
-
연락하다:
- I Nederlof
- 이메일: i.nederlof@nki.nl
-
수석 연구원:
- M Kok, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Signed written informed consent
-
18 years or older at moment of inclusion;
-
Female gender;
-
WHO performance status 0 or 1;
-
Resectable primary breast cancer stage I-III. Nodal status must be examined by ultrasound, fine needle aspiration, sentinel node biopsy, or FDG-PET scan.
-
The tumors must be:
- at least 10 mm (minimum cT1c) as determined by MRI
- TNBC defined as ER<10%, HER2-negative OR luminal B defined as ER≥10%, HER2-negative with either Ki67≥20% or PR =<20% OR grade 3. HER2 negative is defined as an IHC score of <2 or 2+ with a negative ISH.
- For TNBC patients: TIL≥5%
- For LumB breast cancer patients: TIL≥1%
- For cohort 3B: N0 status, TN and TIL ≥50%
- For cohort 4B: N0 status, TNBC and TIL 30-49%
- For cohort 5B: N0 status, TNBC and TIL ≥50% ● Patients with multifocal/multicentric breast cancer are eligible if triple negative breast cancer histology as well as sufficient TIL percentages (30-49% in cohort 4B, ≥50% in cohort 5B) have been confirmed in all tumor lesions.
Exclusion Criteria:
- evidence or suspicion of metastatic disease. Evaluation of the presence of distant metastases may include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and abdomen and/or FDG-PET scan, according to local procedures;
- evidence of a concurrent contralateral or ipsilateral second primary infiltrating breast cancer. Evaluation of the presence of a concurrent second primary breast cancer may include mammography, breast ultrasound and/or MRI breast;
- other malignancy except carcinoma in situ and basal-cell and squamous carcinoma of the skin, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiotherapy
- previous radiation therapy or chemotherapy;
- prior treatment with checkpoint inhibitors (including anti- PD1, -PD-L1, -CTLA-4);
- concurrent anti-cancer treatment, neoadjuvant therapy or another investigational drug;
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 1A; LumB
Nivolumab |
2 courses 240 mg flat dose |
|
실험적: 1B; TNBC
Nivolumab |
2 courses 240 mg flat dose |
|
실험적: 2A; LUMB
Nivolumab and ipilimumab |
2 courses 240 mg flat dose single dose ipilimumab (1mg/kg) at day 1 two courses ipilimumab (1mg/kg) at day 1 and 21 |
|
실험적: 2B; TNBC
Nivolumab and ipilimumab |
2 courses 240 mg flat dose single dose ipilimumab (1mg/kg) at day 1 two courses ipilimumab (1mg/kg) at day 1 and 21 |
|
실험적: 3B; TNBC, High TIL
Nivolumab and ipilimumab |
2 courses 240 mg flat dose single dose ipilimumab (1mg/kg) at day 1 two courses ipilimumab (1mg/kg) at day 1 and 21 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pathological complete response rate per cohort,
기간: up to 3 weeks after surgery, an average of 6 months
|
number of patients with no residual invasively growing tumor cells detected by microscopic examination in breast and axilla |
up to 3 weeks after surgery, an average of 6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events according to NCI Common Toxicity Criteria version 5.0
기간: up to 3 weeks after surgery, an average of 6 months
|
Adverse events in all regimens will be graded according to NCI Common Toxicity Criteria version 5.0. |
up to 3 weeks after surgery, an average of 6 months
|
|
Radiological response rate
기간: At 4 weeks
|
The percentage of patients having a complete response, partial response or stable disease per cohort assessed by MRI |
At 4 weeks
|
|
Immune activation after pre-operative nivolumab, either as monotherapy or in combination with ipilimumab or relatlimab or novel IO combinations.
기간: within 6 months after surgery
|
Immune activation is defined as either a 2-fold increase in tumor-associated CD8 after pre-operative immunotherapy; and/or a 2-fold increase expression of genes induced by IFNy (determined using mRNA expression levels) |
within 6 months after surgery
|
공동 작업자 및 조사자
수사관
- 수석 연구원: M Kok, MD, The Netherlands Cancer Institute
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M18BEL
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
to be determined
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .